Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024

2024-04-04

财报临床3期临床2期引进/卖出

Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.

Webcast Access:

Event: Altamira Therapeutics Full Year 2023 Financial Results and Business Update Call

Date: Wednesday, April 10, 2024

Time: 8:30 am EDT

Webcast URL: https://edge.media-server.com/mmc/p/ijjfu6tm

Registration for Call:

https://register.vevent.com/register/BI2e385f19fe9e405ca2c190f33b9b8e34

Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.

Select a method for joining the call.

Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.

Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.

A replay of the call will be available after the live event and accessible through the webcast link: https://edge.media-server.com/mmc/p/ijjfu6tm

About Altamira Therapeutics

Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com

Investor Contact

Hear@altamiratherapeutics.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Altamira Therapeutics Ltd.

适应症